Kanchi Chadha, MD, FACOG, MSCP, supports reconsidering MHT boxed warnings but says the FDA cited no study behind the change.
News|Articles|September 23, 2026
Menopause proteomic scores associated with cognitive aging, dementia risk
Author(s)Joshua Fitch, Senior Editor
Fact checked by: Benjamin P. Saylor
Menopause proteomics were consistently associated with inflammatory brain aging and Alzheimer’s dementia risk across nearly 15,000 women in a new study published in Nature Medicine.
Advertisement
Advertisement
Using blood proteomics data from multiple cohorts to identify biological changes associated with menopause, the researchers of a new study published in Nature Medicine found that “spontaneous menopause is characterized by dysregulation in inflammatory, synaptic, metabolic, and Alzheimer’s disease biologic processes, which tracked more strongly with hormones than with age.”
Related to this article
Soma Mandal, MD, MSCP, says removing MHT boxed warnings is overdue but calls for transparency on the FDA's product-specific rationale.
A recap of the top video interviews from Contemporary OB/GYN's coverage of The Menopause Society 2026 Annual Meeting in San Diego.
Susan Reed, MD, MPH, MS, and Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, weigh in on FDA boxed warning removals for menopausal hormone therapy.
Joint guidance from the AHA, AAP, ACOG, and SMFM organizes cardiovascular prevention for girls and women around 4 female life stages.
Get caught up with Contemporary OB/GYN's latest coverage from The Menopause Society Annual Meeting in San Diego, California.
Hormone therapy was associated with more frequent, longer migraines in postmenopausal women, but not with greater severity or analgesic use.
Risa Kagan, MD, on bone health prevention in primary care and why baseline bone density testing should come before age 65.
Advertisement
Advertisement